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ABSTRACT: Bacterial biofilm infections incur massive costs on
healthcare systems worldwide. Particularly worrisome are the
infections associated with pressure ulcers and prosthetic, plastic,
and reconstructive surgeries, where staphylococci are the major
biofilm-forming pathogens. Non-leaching antimicrobial surfaces
offer great promise for the design of bioactive coatings to be used
in medical devices. However, the vast majority are cationic, which
brings about undesirable toxicity. To circumvent this issue, we
have developed antimicrobial nanocellulose films by direct
functionalization of the surface with dehydroabietic acid
derivatives. Our conceptually unique design generates non-leaching anionic surfaces that reduce the number of viable staphylococci
in suspension, including drug-resistant Staphylococcus aureus, by an impressive 4−5 log units, upon contact. Moreover, the films
clearly prevent bacterial colonization of the surface in a model mimicking the physiological environment in chronic wounds. Their
activity is not hampered by high protein content, and they nurture fibroblast growth at the surface without causing significant
hemolysis. In this work, we have generated nanocellulose films with indisputable antimicrobial activity demonstrated using state-of-
the-art models that best depict an “in vivo scenario”. Our approach is to use fully renewable polymers and find suitable alternatives to
silver and cationic antimicrobials.
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■ INTRODUCTION
Bacterial attachment and subsequent biofilm formation
significantly hinder surface performance in a plethora of
circumstances including food packaging, sanitary and house-
hold materials, as well as military and medical items.1−4 As a
consequence, the colonization of surfaces by bacteria has been
under intensive research aiming at finding guiding principles to
efficiently manipulate bacteria−surface interactions for the
benefit of humans.5−9 From a health perspective, the most
worrisome biofilm-based infections are those associated with
implanted medical devices; chronic wounds (including
pressure ulcers); and prosthetic, plastic, and reconstructive
surgeries.10−13 Biofilms are difficult to treat once established as
microorganisms in biofilms are inherently tolerant and resistant
to antimicrobial therapies. In addition, dispersal of bacterial
cells from biofilms carries a very significant risk of infection
dissemination within the host. Not surprisingly, biofilm-based
infections and associated complications currently incur massive
financial costs on healthcare systems.1−4 Therefore, clinical and
economic benefits will surely accrue from improved anti-
microbial coatings that efficiently limit bacterial attachment as
an alternative to treating mature biofilms.
The design of antimicrobial surfaces comprises chemical
engineering of the surface to either leach biocides or kill
bacteria directly upon contact.3,4 Remarkable progress in this
field has led to antibacterial surfaces with varying degrees of
complexity14−20 based, for instance, on enzymes, antimicrobial
peptides, bacteriophages, polycations, graphene oxides, plasma
technology, and several metal antimicrobials of which silver,
despite its well-known toxicity to human cells and to the
environment, is the most widely used. One of the major
disadvantages of the leaching approach is that the surface
progressively becomes ineffective as the antimicrobial species
leaves the material, thereby severely limiting the surface
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durability. In contrast, non-leaching contact-active surfaces are
envisioned to be longer-lasting and even susceptible to
reactivation by treatment with appropriate solvents, while
protecting the environment from contamination with anti-
microbials.
The tight electrostatic interactions that positively charged
nanomaterials establish upon contact with the negatively
charged functional groups at the surface of bacteria have been
extensively exploited in the design of contact-active anti-
bacterial surfaces, albeit the well-documented toxicity of
polycationic compounds.21−24 In contrast, anionic surfaces
circumvent this toxicity issue because they fail to induce the
strong membrane polarization that leads to cell lysis.
Nonetheless, they remain greatly unexplored. A few reports
document that nanoparticles with a negatively charged surface
interact extensively through hydrogen bonding with lip-
opolysaccharides and/or peptidoglycans at the surface of
bacteria that are responsible for structural integrity and
survival, thus causing cell death, while bypassing general
toxicity.25,26 Carboxylate-functionalized polystyrene nanopar-
ticles with a precise diameter have also been reported to
interfere with specific surface proteins of fungi that influence
key events in adhesion to abiotic surfaces and host tissues.27
In an era of increasing awareness of the need to replace
petroleum-based polymers for alternatives widely abundant
from natural sources, cellulose nanofibrils (CNFs), a fully
renewable and biocompatible material, are an attractive starting
point for the design of bioactive coatings.28−32 Films made
from CNFs combine sustainability with outstanding mechan-
ical properties33 and are envisioned to be able to replace
synthetic polymer-based films in flexible electronics, medical
devices, or food packaging.28−32 Despite the fact that there are
several reports detailing both leaching and non-leaching
methods to make CNF antimicrobial,34−40 CNF films that
combine non-leaching and antimicrobial properties with good
biocompatibility, in a way to preserve the physico-chemical
properties needed for the envisioned applications, are currently
lacking. In fact, only a few reports37−39 detail the synthesis of
non-leaching antimicrobial CNF; however, these comprise
highly cationic compounds37 well known for their cyto- and
ecotoxicities or are likely to have limited chemical stability
because of the use of antimicrobial proteins38 and grafting
strategies based on reversible chemical reactions.39 In this
work, we present the first example of anionic CNF films
modified with dehydroabietic acid derivatives that efficiently
resist fouling by bacteria in an artificial dermis model
mimicking the wound environment. We determine details of
the chemical composition of the surface and discuss how these
relate to the efficient antimicrobial activity observed. Recently,
a wound dressing based on wood-derived CNF (FibDex)41
was launched in the European market, showing the potential of
CNF for the design of medical devices for human use alongside
with bacterial cellulose and carboxymethyl cellulose (CMC).
■ RESULTS AND DISCUSSION
For the synthesis of CNF-CMC-7a and CNF-CMC-7b (Figure
1), an attachment point at C12 of the dehydroabietic acid
derivative was designed, with a spacer length of three carbon
atoms. In order to achieve this, dehydroabietic acid 1 was
selected as the starting material for the synthesis of compounds
7a and 7b, by means of a six-step sequence (Figure 2).
Compound 7a is capped with a methyl ester at C18, whereas
compound 7b bears a cyclohexyl-L-alanine moiety, previously
reported to be relevant for the antimicrobial activity of
dehydroabietanes.42−45 For the synthesis of 7a, compound 1
was first converted into its methyl ester 2a to undergo Friedel−
Crafts acylation reaction and give 3a. Compound 2b was
prepared by N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
(EDC)-mediated coupling of β-cyclohexyl-L-alanine methyl
ester hydrochloride to 1. Peracetic acid-mediated oxidation of
3a/3b in acetic acid, followed by treatment with a base, gave
5a/5b, which was reacted with t-Bu-(3-bromopropyl)-
carbamate to give 6a/6b. Compounds 7a/7b were prepared
after deprotection of the amino group by treatment with
trifluoroacetic acid (TFA). Each compound was reacted with
CNF films using carbodiimide chemistry after the surface was
Figure 1. Synthesis of CNF-CMC-7a and CNF-CMC-7b and chemical detail of the surface composition. Reagents and conditions: (i) CaCl2/
NaHCO3, Na-CMC, 80 °C, 4 h and (ii) EDC·HCl, DIPEA, HOBt, 7a or 7b, r.t., 24 h.
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enriched in free carboxyl groups by adsorption of CMC
(Figure 1).
X-ray photoelectron spectroscopy (XPS) was used to probe
the surface composition prior to and after functionalization
with compounds 7a and 7b (Table 1, Figure 3A,B).
Specifically, nitrogen content and the presence of the ester
groups were analyzed. Indeed, as expected, nitrogen was found
on the functionalized films CNF-CMC-7a and CNF-CMC-7b
only, and the content of C−C, that is, carbon atoms without
oxygen neighbours, increased after the functionalization
because of the presence of the dehydroabietic acid derivative
bound at the surface. In good agreement, the content of carbon
atoms with one bond to oxygen (C−O) was lower after the
functionalization, while the content of carbon atoms with one
single and one double bond to oxygen (O−CO), derived
from carboxyl groups, increased. Using relative C−C or N
content, it was estimated that 7a covers no more than 20−30%
of the surface of CNF-CMC-7a, whereas 7b covers about 14−
25% of the of the surface of CNF-CMC-7b.
Additional confirmation of the success of the coupling
reaction was gathered from the time-of-flight secondary ion
mass spectrometry (ToF-SIMS) analysis of CNF, CNF-CMC,
CNF-CMC-7b, and single compound 7b (Figure 3C,D and
Figures S17, S18). A number of ions46,47 were observed in the
spectra of compound 7b, including a peak corresponding to
the protonated molecular ion [M + H]+ at m/z 541.5 in the
positive ion mass spectrum (Figure 3C). The corresponding
deprotonated molecular ion peak [M − H]− was weakly
observed in the negative ion spectrum at m/z 539.4 (Figure
3D). As expected, these peaks did not show up in either CNF
or CNF-CMC but were present in the spectra of CNF-CMC-
7b. Further evidence of the attachment of 7b to the surface
CMC was suggested by the peak at m/z 696.7 (Figure 3C),
which was proposed to correspond to a monomeric CMC
fragment bound to 7b with a cleavage at its ring A amide bond,
resulting in loss of the cyclohexylalanine group.
Electrokinetic (streaming current) measurements at varying
pH values of 1 mM KCl solutions revealed a negatively
charged interface for CNF-CMC-7b that can be attributed to
the ionization of carboxyl groups (Figure 4A).48,49 The
interface generated by both CNF-CMC and CNF-CMC-7b
showed a rather similar “electrokinetic fingerprint”. The slight
differences can be assigned to differences in the density and
ionization of carboxyl groups as well as the impact of the
interfacial structure on the electrohydrodynamics in the
electrokinetic active region of the interface.49 The lack of
significant differences between both films corroborates the
evidence collected from the XPS analysis, where it was
estimated that the amount of compound 7b that covers the
surface is indeed relatively low.
As the functionalization of the films occurred only at the
surface, no significant changes in the FTIR spectra were seen
when comparing CNF, CNF-CMC, CNF-CMC-7a, and CNF-
CMC-7b (Figure 4B). Surface morphology also remained
unchanged (Figure S19). Nonetheless, as expected, the
hydrophobicity of both CNF-CMC-7a and CNF-CMC-7b
clearly increased in relation to CNF, as shown by the water
contact angle values changing from 31.4 to 86.1 and 75.3°,
respectively, due to the increased content of carbon and
hydrogen at the surface of the abietane-containing films
(Figure 4C). However, the static water contact angle
measurements at 5 and 30 s showed that both CNF-CMC-
7a and CNF-CMC-7b were still intrinsically hydrophilic (θ <
90°).50
The activity of CNF-CMC-7b was evident against
planktonic Gram-positive staphylococci when compared to
Figure 2. Synthesis of compounds 7a and 7b. Reagents and
conditions: (i) CH3I, K2CO3, DMF, r.t. for 2a; (ii) EDC·HCl,
DIPEA, HOBt, β-cyclohexyl-L-alanine methyl ester hydrochloride,
DMF, r.t., 24 h for 2b; (iii) AcCl, CH2Cl2, 0 °C to r.t.; (iv) AcOOH/
AcOH, CH2Cl2, r.t; (v) K2CO3, MeOH, r.t.; (vi) t-Bu-(3-
bromopropyl)carbamate, Cs2CO3, DMF, r.t; and (vii) TFA,
CH2Cl2, 0 °C. aCrude yield. bYield after chromatographic purification.
Table 1. High Resolution Numerical XPS Data for CNF, CNF-CMC-7a, and CNF-CMC-7b
wide scan atomic concentrations [%] (SD)c high resolution C 1s carbon fits [%] (SD)c
sample C 1s O 1s N 1s Si 2p C−C C−O O−C−O O−CO
CNF 60.7 (0.5) 39.3 (0.5) 0.0 (0.0) 0 (0.0) 4.4 (0.0) 74.5 (0.2) 19.2 (0.1) 1.9 (0.0)
CNF-CMC-7aa 63.6 (1.3) 35.5 (1.3) 1.0 (0.0) 0 (0.0) 16.7 (1.1) 63.3 (1.1) 17.4 (0.1) 2.6 (0.1)
CNF-CMC-7bb 62.8 (0.4) 35.3 (0.3) 1.2 (0.1) 0.5 (0.2) 13.0 (0.6) 66.2 (1.0) 17.9 (0.7) 2.7 (0.2)
aSurface coverage for CNF-CMC-7a was estimated as 30% based on N content and 20% based on C−C content. bSurface coverage for CNF-
CMC-7b was estimated as 25% based on N content and 14% based on C−C content. cStandard deviation (n = 3).
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unmodified CNF. CNF-CMC-7b films were able to produce
approximately 4 and 5 log reductions in viable Staphylococcus
aureus ATCC12598 cell counts and the methicillin-resistant
strain MRSA 14TK301 strains after 24 h of contact,
respectively (Figure 5A,B). Good activity was also observed
against Gram-negative Escherichia coli with a reduction in
bacterial counts of approximately 2 log units. CNF-CMC-7a
was overall less potent but still able to target both Gram-
positive and -negative bacteria. CNF-CMC-7b was selected for
further studies including assessment of cell proliferation at the
surface and toxicity toward blood cells (Figure 5C) as well as
the ability to resist to bacterial colonization in both a biofilm
model and an artificial dermis model that simulates a chronic
wound environment51 (Figure 6). Human fibroblasts prolif-
erated to a larger extent at the surface of CNF-CMC-7b than
they did at the surface of CNF, and only very minor
haemolysis (1.8%) was induced by the presence of the
modified films (Figure 5C).
In addition, the ability of CNF-CMC-7b to resist fouling by
the virulent oxacillin-susceptible clinical isolate UAMS-1 was
noteworthy. CNF-CMC-7b caused an average reduction in
recovered CFU of 2.5 log units when compared to CNF in the
biofilm model (Figure 6A). This result translated well into the
wound model where CNF-CMC-7b was placed on top of the
artificial dermis, and there was a clear reduction in the CFU
recovered (1.4 log units) when compared to CNF (Figure 6B).
As evidenced in the pictures, CNF-CMC-7b efficiently resisted
colonization by UAMS-1. It should be noted that the artificial
dermis model uses high concentrations of plasma and horse
blood to moisten the dermis, so evidently the activity of CNF-
CMC-7b is not hampered by plasma protein binding. As
expected, as CNF-CMC-7b contacted only with the outer
surface of the artificial dermis which is roughly 1 cm thick,
there was no significant difference in CFU recovery between
the artificial dermises contacted with either CNF-CMC-7b or
CNF after 24 h of biofilm formation because of the non-
leaching, contact-active properties of CNF-CMC-7b (Figure
6C).
The mode of antimicrobial action of the CNF films designed
from compounds 7a and 7b does not necessarily have to
recapitulate the mode of action of the isolated compounds as
these do not leave the surface of the films and are therefore
unlikely to permeate the bacterial wall. Indeed, compound 7a
is devoid of significant antimicrobial activity, whereas 7b is
active against Gram-positive strains only, including S. aureus
ATCC12598, UAMS-1, and the methicillin-resistant, vanco-
mycin (Van)-intermediate resistant S. aureus Mu50 (Table 2,
Figure 7). Treatment of S. aureus ATCC12598 with a 7×
minimum inhibitory concentrations (MIC) concentration of
7b for a short period of time does not seem to cause extensive
bacterial cell lysis, suggesting that it is a slow acting compound
(Figure 7A). In sharp contrast, both CNF-CMC-7a and CNF-
CMC-7b are active against Gram-positive and -negative
bacteria. CNF-CMC-7b in particular is active against Gram-
negative E. coli DH5α (Figure 5B), whereas compound 7b is
inactive even at a high concentration of 400 μM (Table 2).
Scanning electron micrographs of S. aureus ATCC12598
after exposure to CNF-CMC-7b showed extensive background
debris and bacteria with rough surfaces and bubble-like
protrusions, indicating severe damage to the cell wall (Figure
8). After treatment with 7b, a few intact bacteria could be
observed along with cell debris.
The key to understanding the potential mode of action of
surfaces generated from CNF films and dehydroabietic acid
Figure 3. (A) XPS wide scan of CNF and CNF-CMC-7b with close-up of the N 1s signal. (B) High resolution C 1s spectra of CNF and CNF-
CMC-7b. (C) Positive ion ToF-SIMS mass spectrum and (D) negative ion ToF-SIMS mass spectrum of CNF, CNF-CMC, CNF-CMC-7b, and
compound 7b.
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derivatives such as compounds 7a or 7b resides in close
inspection of the details of the chemistry generated at the
surface (Figure 1). This highly heterogeneous film surface
comprises unreacted carboxyl groups from the adsorbed CMC
(pKa 3.6)
52 that will be ionized at pH 7 and a small number of
nonionizable, amide-bonded 7a/7b fingers, unevenly distrib-
uted throughout the CMC backbone. The overall surface is
likely to be perceived by bacteria as a complex anionic sugar-
based polymeric matrix unevenly branched with the com-
pound, where hydrophilic and hydrophobic regions are not
clearly separated but instead have a mosaic distribution of
polarity, that is, CNF-CMC-7a and CNF-CMC-7b bear
“imperfect amphipathicity”.53 This property has been
described in biosurfactants produced by microorganisms,
such as glycolipids, lipopeptides or saponins, and is responsible
for their ability to intercalate into bacterial membranes, bind to
surface proteins, and extract lipopolysaccharides to modulate
biofilm formation below their critical micellar concentration.54
The mosaic distribution of polarity in biosurfactants is an
essential property that distinguishes them from chemical
surfactants with clearly separated distribution of polarity
because the former cannot bind so strongly to positively
charged groups in proteins and do not solubilize membranes.
For CNF-CMC-7b, it may help to explain why fibroblasts grow
well at its surface and why it does not induce significant
haemolysis of red blood cells, unlike the nonionic chemical
surfactant Triton-X (Figure 5C).
The anionic net charge is reported as yet another essential
feature for the interactions of biosurfactants with surface
proteins.54 In this context, we tried to rule out whether CNF-
CMC-7b significantly affected autolysins, which are the key
enzymes at the surface of bacteria, responsible for cell
Figure 4. (A) Streaming current vs pressure gradient measurements
for CNF, CNF-CMC, and CNF-CMC-7b; (B) Fourier-transform
infrared (FTIR) spectra of CNF, CNF-CMC, CNF-CMC-7a, and
CNF-CMC-7b with graphics normalized by the 1159 cm−1 band; (C)
water contact angle measurements at 5 and 30 s for CNF, CNF-
CMC-7a, and CNF-CMC-7b. CNF-CMC is very hydrophilic and
does not allow accurate water contact angle determination.
Figure 5. (A) Amount of viable MRSA 14TK301 from 10% of ∼105
colony forming units (CFU)/mL cell suspensions, after 24 h of
incubation with CNF or CNF-CMC-7b. CNF-CMC was devoid of
significant antimicrobial activity as previously reported;57 (B)
antimicrobial activity of CNF, CNF-CMC-7a, and CNF-CMC-7b.
◆; = not tested. Statistical analysis was made using a 2-tailed
independent t-test where, CNF-CMC-7a and CNF-CMC-7b were
compared to CNF, *p < 0.05. (C) Human fibroblast viability
(measured in terms of percent of viable fibroblasts placed on top of
each material compared to the percent of viable fibroblasts grown on a
sterile tissue culture-treated 24-well control plate) and haemolysis
testing (measured in terms of percent of haemolyzed erythrocytes
from the 2% Triton X-100 solution) for CNF and CNF-CMC-7b.
Statistical analysis was made by one-way ANOVA, followed by a
Dunnett’s multiple comparison test. All data sets were compared with
CNF, and the levels of significance were set at probabilities of *p <
0.05, **p < 0.01, and ***p < 0.001, (n = 4), n.s.= not significant.
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separation and cell wall turnover. Autolysins exist attached to
the cell surface but can be released by high salt treatment and
are well known to mediate cell-to-cell adherence and biofilm
formation through binding to vitronectin and fibronectin.55
Cell wall active antibiotics can interfere with autolysins, but
this is usually considered a post-mortem event as they will
cause killing first by inhibiting peptidoglycan synthesis.56
Investigations in small molecules or vaccines that can modulate
the activity of these autolysins are still at their infancy but have
the potential to generate a new class of antimicrobial agents.57
We found that CNF-CMC-7b was only 10-fold less active
against a mutant strain of the Gram-positive Lactococcus lactis
(LAC471) devoid of the AcmA autolysin than against the
original L. lactis LAC460 strain (data not shown), suggesting
that it is unlikely that release of autolysins from bacteria
surfaces can be regarded as the sole mechanism of action of the
films. Instead, the activity of multiple surface proteins with
relevance to the integrity and biofilm-forming ability of
bacteria is bound to be affected by CNF-CMC-7b. As an
anionic surface with sugar units, CNF-CMC-7b could easily
bind to positively charged residues and/or carbohydrate
recognition sites of specific surface proteins or even indirectly
modulate their activity through ion chelation in a similar
fashion to what has been described for nanoparticles.22,23,25−27
A potential suppressor of potency for CNF-CMC-7b in Gram-
negative E. coli is the ability of the O-antigen to systematically
hamper adhesion onto cells by completely neutralizing the
negative charge carried by the supporting cell envelope.26
Despite these general considerations, there is yet another
feature of CNF films functionalized with dehydroabietic acid
derivatives that is highly relevant when discussing their
potential mode of action. In line with our previous
observations,58 charge, hydrophobicity, and surface topography
Figure 6. (A) CFU count after 24 h of UAMS-1 biofilm formation on CNF and CNF-CMC-7b. Statistical analysis was done using a 2-tailed
independent t-test. CNF-CMC-7b showed an average reduction in recovered CFU of 2.5 log (95% CI: 1.7−3.4, p < 0.05, n = 11) compared to
CNF. The dotted line indicates the detection limit; (B) CFU count from CNF and CNF-CMC-7b placed on infected (UAMS-1) artificial dermis.
Statistical analysis was done using a 2-tailed independent t-test. CNF-CMC-7b showed an average reduction in recovered CFU of 1.4 log (95% CI:
0.9−1.9, p < 0.05, n = 9) compared to CNF. The pictures show bacterial colonization of CNF and CNF-CMC-7b of the material placed on top of
infected artificial dermis after 24 h; (C) CFU count from artificial dermis after 24 h of UAMS-1 biofilm formation. Statistical analysis was done
using a one-way ANOVA Bonferroni analysis. There was no significant difference for recovered CFU between the artificial dermises (n = 9).
Table 2. Antimicrobial Activity of Compounds 7a and 7ba
MIC (μM)
compound S. aureus ATCC12598 UAMS-1 Mu50 E. coli DH5α
7a 60 N.D.c N.D. 130
7b 15 7.4 7.4 N.A.b
aMIC = minimum inhibitory concentration. bN.A. = not active at the
maximum concentration tested (400 μM). cN.D. = not determined.
Figure 7. (A) Release of ATP from S. aureus ATCC12598 after
incubation with compounds 7a or 7b (100 μM) or Van (100 μM).
NT = untreated cells; (B) fluorescence images depict S. aureus
ATCC12598 or E. coli DH5α counts with/without treatment with
compounds 7a or 7b, at 100 μM, for 1 h.
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alone do not account for the bioactivity of the functionalized
CNF films. However, changes in the compound bound at the
surface of the film seem to be determinant. This is clearly
evidenced by the fact that CNF-CMC-7a is weakly
antimicrobial, whereas CNF-CMC-7b, where a β-cyclohexyl-
L-alanine side chain was introduced in place of the simple
methyl ester using the exact same spacer unit to CMC, is much
more potent. It is therefore reasonable to speculate that the
spatial orientation and binding distance of the abietane to the
CMC backbone play a crucial role not only in the mosaic
distribution of polarity and changes to the hydrophobicity but
also in targeting specific chemical space/structures at the
surface of the bacteria that trigger the antimicrobial action. The
ability to fully elucidate details of the chemical space/
structures will depend on future advances in techniques that
are able to probe and/or model the processes occurring in the
contact region between the surface and bacteria at the atomic
scale. Understanding the exact nature of the interactions of
surfaces based on dehydroabietic acid derivatives and CNF will
undoubtedly pave the way for the development of more
efficient and biocompatible antimicrobial surfaces.
■ CONCLUSIONS
We have successfully developed, for the first time, non-
leaching, anionic, and biocompatible CNF films with the ability
to resist colonization by bacteria that would lead to the
undesirable establishment of a biofilm, when tested in a model
that mimics the physiological conditions present in chronic
wounds. By covalently coupling the dehydroabietic acid
derivatives 7a or 7b at the surface of premade activated
CNF films, we have created an interface with bacteria where
the film is most likely perceived as an anionic sugar-based
polymeric matrix unevenly branched with the compound,
where hydrophilic and hydrophobic regions are not clearly
separated. This uneven distribution of polarity combined with
the spatial orientation and the binding distance of the
compound to the CMC backbone at the surface of the films
are likely to be the key contributors to the observed bioactivity.
The activity of the films made from compound 7b was
particularly good and more relevant in Gram-positive bacteria,
remaining unaffected by the presence of high protein content.
This finding together with the remarkable biocompatibility of
the films suggests that there is a great potential for using them
as integral parts of advanced biomaterials for human health
including prosthetic implants or vascular stents, where S.
aureus is a prevalent biofilm-forming pathogen.
■ EXPERIMENTAL SECTION
Compound and Film Synthesis. Dehydroabietic acid (90%
purity) was purchased from Pfaltz & Bauer Inc. Acetyl chloride,
iodomethane, aluminium chloride, N,N-diisopropylethylamine
(DIPEA), 1-hydroxybenzotriazole hydrate (HOBt), di-t-butyl dicar-
bonate, cesium carbonate, sodium CMC (DS 0.70−0.85, MW ∼
250,000), N,N-dimethylformamide (DMF), cyclohexane, ethyl
acetate, hexane, heptane, methanol, and dichloromethane were
acquired from Sigma-Aldrich Co. t-Butyl (3-bromopropyl)carbamate
was acquired from Ega-Chemie. N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC·HCl), (S)-methyl 2-amino-
3-cyclohexylpropanoate hydrochloride, and TFA were purchased from
Fluorochem Ltd. Calcium chloride and potassium chloride were
purchased from Merck & Co. Sodium bicarbonate was purchased
from VWR International Oy and ethanol (Etax A, 94%) was
purchased from Altia Oyj. All reagents were used without purification.
Silica gel 60 F254 was used for thin layer chromatograph. Flash
column chromatography was made using a Biotage high-performance
flash chromatography SP4-system (Uppsala, Sweden) with a 0.1 mm
path length flow cell UV detector/recorder module (fixed wavelength:
254 nm) and SNAP cartridges (25, 50 or 100 g) at 25−100 mL/min
flow rate. A Vertex 70 (Bruker Optics Inc., MA, USA) instrument was
used to record FTIR spectra of the compounds and films using a
horizontal attenuated total reflectance (ATR) accessory (MIRacle,
Pike Technology, Inc., WI, USA). Transmittance was recorded at 4
cm−1 resolution, between 4000 and 600 cm−1, using OPUS 5.5
software (Bruker Optics Inc., MA, USA). The FTIR graphics of the
films are normalized by the 1159 cm−1 band. Nuclear magnetic
resonance (NMR) spectra of compounds were recorded on a Bruker
Ascend 400 spectrometer using CDCl3 with tetramethylsilane (TMS)
as the internal standard. Chemical shifts are reported in parts per
million (ppm) on the δ scale from TMS as an internal standard, and
the coupling constants J are quoted in hertz (Hz). Exact mass analyses
of the compounds were made with a Waters UPLC-ESI/QTOF-MS
using a Synapt G2 HDMS (Waters, MA, USA) instrument.
Compounds 3b, 4b, 5b, 6a, 6b, 7a, and 7b are novel and have not
been reported before.
Methyl Dehydroabietate (2a). Dehydroabietic acid 1 (0.500 g,
1.50 mmol) was dissolved in DMF (4 mL) at room temperature, and
K2CO3 (573 mg, 4.15 mmol) and iodomethane (0.20 mL, 3.32
mmol) were added. The reaction was left under magnetic stirring for
3 h and 15 min after which it was diluted with 1 M hydrochloric acid
(50 mL) and extracted with diethyl ether (3 × 75 mL). The resulting
Figure 8. SEM of S. aureus ATCC12598 (∼108 CFU/mL) after treatment with CNF and CNF-CMC-7b and 7b, for 24 h. Left panel magnification
3000× and right panel magnification: 50,000×.
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organic phase was washed with 1 M hydrochloric acid (50 mL), a
saturated solution of NaHCO3 in H2O (50 mL), water (50 mL), and
brine (50 mL), dried with anhydrous Na2SO4, filtered, and evaporated
under reduced pressure to give compound 2a as yellow oil (0.461 g,
88%), which was used without further purification. 1H NMR (400
MHz, CDCl3): δ 7.16 (d, J = 8.4 Hz, 1H, aromatic-H), 7.00 (dd, J =
8.4, 1.5 Hz, 1H, aromatic-H), 6.88 (d, J = 1.6 Hz, 1H, 14-H), 3.66 (s,
3H, OCH3), 2.77−287 (m, 3H), 2.30 (d, J = 12.4 Hz, 1H), 2.24 (dd,
J = 12.8, 2.2 Hz, 1H), 1.27 (s, 3H), 1.23 (s, 3H), 1.21 (d, J = 1.2 Hz,
6H). 13C NMR (101 MHz, CDCl3): δ 179.2, 147.0, 145.7, 134.7,
126.9, 124.2, 123.9, 51.9, 47.7, 44.9, 38.0, 37.0, 36.7, 33.5, 30.0, 25.1,
24.0, 21.7, 18.6, 16.5. FTIR (ATR): 2927, 1721, 1247, 1174, 823
cm−1. All analytical data are in agreement with literature values.59
Methyl N-(Abiet-8,11,13-trien-18-oyl) Cyclohexyl-L-alani-
nate (2b). Dehydroabietic acid 1 (7.60 g, 22.8 mmol) was dissolved
in DMF (80 mL). EDC·HCl (7.28 g, 38.0 mmol) and HOBt
monohydrate (5.13 g, 38.0 mmol) were added, and the mixture was
stirred for 2.25 h. β-Cyclohexyl-L-alanine methyl ester hydrochloride
(8.42 g, 38.0 mmol) and DIPEA (13 mL, 74.6 mmol) were added,
and the mixture was stirred at room temperature for another hour.
The mixture was then diluted with water (150 mL) and extracted with
diethyl ether (2 × 300 mL). The resulting organic phase was washed
with 1 M hydrochloric acid (200 mL), a saturated solution of
NaHCO3 in H2O (200 mL), water (200 mL), and brine (50 mL) and
then dried with anhydrous Na2SO4. The mixture was filtered and
evaporated under reduced pressure. After evaporation of solvents, the
white solid powder 2b was obtained (11 g, 93%) and used without
further purification. All analytical data are in agreement with literature
values.59 1H NMR (400 MHz, CDCl3): δ 7.16 (d, J = 8.4 Hz, 1H,
aromatic-H), 6.99 (dd, J = 8.4, 2.0 Hz, 1H, aromatic-H), 6.88 (d, J =
2.0 Hz, 1H, 14-H), 6.11 (d, J = 8.1 Hz, 1H, NH), 4.64−4.70 (m, 1H,
NH(CH)−), 3.71 (s, 3H, OCH3), 2.76−2.98 (m, 3H), 2.32 (d, J =
13.2 Hz, 1H), 2.09 (dd, J = 12.4, 2.1 Hz, 1H), 1.47−1.85 (m, 17H),
1.23 (s, 3H), 1.22 (s, 3H), 1.21 (s, 3H), 0.86−1.00 (m, 3H), 0.75−
0.85 (m, 3H). 13C NMR (101 MHz, CDCl3): δ 178.2, 174.0, 147.0,
145.8, 134.7, 127.0, 124.1, 123.9, 52.2, 50.2, 47.3, 45.8, 40.1, 38.1,
37.3, 37.2, 34.4, 33.6, 33.5, 32.4, 30.0, 26.4, 26.3, 26.1, 25.3, 24.0,
23.9, 21.1, 18.8, 16.4 cm−1. FTIR (ATR): 3364, 2923, 1743, 1638,
1514, 1445, 1201, 822 cm−1. UPLC−HRMS m/z: calcd for
C30H46NO3, 468.3478 [M + H]
+; found, 468.3479.
Methyl 12-Acetylabieta-8,11,13-trien-18-oate (3a). Com-
pound 2a (2.00 g, 6.36 mmol) was dissolved in CH2Cl2 (31 mL)
and then AcCl (1.16 mL, 14.0 mmol) was added to the mixture. The
reaction was left stirring, at 0 °C, for 5 min, after which AlCl3 (1.70 g,
12.7 mmol) was added, and the mixture was left to agitate, for 45 min,
at 0 °C. Then, the reaction mixture was stirred at room temperature
for another hour, after which it was completed. The mixture was
concentrated under reduced pressure, diluted with a saturated
solution of NaHCO3 in H2O (30 mL), and extracted with diethyl
ether (3 × 50 mL). The resulting organic phase was washed with a
saturated solution of NaHCO3 in H2O (2 × 50 mL) and brine (50
mL), dried with Na2SO4, filtered, and evaporated to dryness to yield
3a as a white solid powder (2.02 mg, 89%) that was used without
further purification. 1H NMR (400 MHz, CDCl3): δ 7.39 (s, 1H,
aromatic-H), 7.04 (s, 1H, aromatic-H), 3.67 (s, 3H, COCH3), 3.46
(sept, J = 6.8 Hz, 1H, 15-H), 2.90 (dd, J = 8.8, 4.4 Hz, 2H), 2.55 (s,
3H, OCH3), 2.31 (d, J = 12.4 Hz, 1H), 2.22 (dd, J = 12.4, 2.4 Hz,
1H), 1.28 (s, 3H), 1.18−1.23 (m, 9H). 13C NMR (101 MHz,
CDCl3): δ 203.4, 179.0, 146.6, 144.9, 138.8, 136.4, 127.0, 124.3, 52.0,
47.6, 44.7, 37.9, 36.9, 36.6, 30.5, 30.0, 28.7, 25.1, 24.3, 24.1, 21.5,
18.5, 16.5. FTIR (ATR): 2926, 1725, 1681, 1248, 881 cm−1. UPLC−
HRMS m/z: calcd for C23H33O3, 357.2430 [M + H]
+; found,
357.2431. All analytical data are in agreement with literature values.59
Methyl 12-Acetyl-N-(abiet-8,11,13-trien-18-oyl) Cyclohexyl-
L-alaninate (3b). Compound 2b (9.80 g, 21.0 mmol) was dissolved
in dichloromethane (128 mL); then, AcCl (5.2 mL, 73.5 mmol) was
added to the mixture. The reaction mixture was left to stir at 0 °C for
5 min, after which AlCl3 (8.40 g, 63.0 mmol) was added and the
mixture was left to agitate for 45 min at 0 °C. The reaction mixture
was left to stir at room temperature for 2.5 h, concentrated under
reduced pressure, diluted with water (70 mL), and extracted with
ethyl acetate (2 × 300 mL). The resulting organic phase was washed
with water (100 mL), a saturated solution of NaHCO3 in H2O (100
mL), and brine (50 mL), dried with Na2SO4, filtered, and evaporated
to dryness. The residue was purified by flash chromatography (SNAP
100 g, cyclohexane/ethyl acetate, gradient 8 → 80%). After
evaporation of solvents, the white solid 3b was obtained (1.67 g,
56%). 1H NMR (400 MHz, CDCl3): δ 7.39 (s, 1H, aromatic-H), 7.04
(s, 1H, aromatic-H), 6.09 (d, J = 8.0 Hz, 1H, NH), 4.65−4.71 (m,
1H, NH(CH)−), 3.73 (s, 3H, COCH3), 3.46 (sept, J = 6.8 Hz, 1H,
15-H), 2.86−2.99 (m, 2H), 2.55 (s, 3H, OCH3), 2.33 (d, J = 12.8 Hz,
1H), 2.11 (dd, J = 12.4, 2.0 Hz, 1H), 1.48−1.86 (m, 16H), 1.31 (s,
3H), 1.24 (s, 3H), 1.20 (dd, J = 12.4, 6.4 Hz, 7H), 0.81−1.00 (m,
3H). 13C NMR (101 MHz, CDCl3): δ 203.3, 178.0, 174.0, 146.6,
145.0, 138.8, 136.4, 127.1, 124.3, 52.3, 50.2, 47.2, 45.5, 40.1, 37.9,
37.1, 34.5, 33.6, 32.4, 30.6, 30.0, 28.7, 26.4, 26.3, 26.1, 25.3, 24.3,
24.1, 20.9, 18.6, 16.5 cm−1. FTIR (ATR): 3360, 2923, 1744, 1641,
1517, 1260, 1201, 887. UPLC−HRMS m/z: calcd for C32H48NO4,
510.3583 [M + H]+; found, 510.3583.
Methyl 12-Acetoxyabieta-8,11,13-trien-18-oate (4a). Com-
pound 3a (1.88 g, 5.27 mmol) was dissolved in CH2Cl2 (7.4 mL). A
solution of peracetic acid (36−40%, 12.3 mL, 199 mmol) in AcOH
was added to the mixture, and the reaction mixture was left stirring at
room temperature for 96 h, after which the reaction was completed.
The reaction mixture was quenched by the addition of water (70 mL),
and the resulting mixture was extracted with diethyl ether (4 × 70
mL). The resulting organic phases were combined and washed with a
saturated solution of NaHCO3 in H2O (2 × 50 mL) and brine (50
mL) and then dried with Na2SO4. The mixture was filtered,
evaporated under reduced pressure, and purified by flash chromatog-
raphy (SNAP 50 g, n-heptane/ethyl acetate, 3:1). After evaporation of
solvents, the yellow powder 4a was obtained (1.73 g, 88%). 1H NMR
(400 MHz, CDCl3): δ 6.94 (s, 1H, aromatic-H), 6.82 (s, 1H,
aromatic-H), 3.66 (s, 3H, OCOCH3), 2.84−2.93 (m, 3H), 2.30 (s,
3H, OCH3), 2.23 (dd, J = 12.4, 2.4, 1H), 2.17 (d, J = 4.0 Hz, 1H),
1.26 (s, 3H), 1.20 (s, 3H), 1.18 (t, J = 7.0 Hz, 6H). 13C NMR (101
MHz, CDCl3): δ 179.0, 170.0, 148.1, 146.2, 137.0, 132.9, 127.0,
117.8, 52.0, 48.0, 44.5, 37.9, 37.0, 36.6, 29.5, 27.2, 25.0, 23.1, 23.0,
21.6, 21.0, 18.5, 16.5. FTIR (ATR): 3428, 2932, 1723, 1206, 909
cm−1. UPLC−HRMS m/z: calcd for C23H33O4, 373.2379 [M + H]+;
found, 373.2383. All analytical data are in agreement with literature
values.59
Methyl 12-Acetoxy-N-(abiet-8,11,13-trien-18-oyl) Cyclohex-
yl-L-alaninate (4b). Compound 3b (5.90 g, 11.6 mmol) was
dissolved in dichloromethane (24 mL). A solution of peracetic acid
(36−40%, 39 mL, 530 mmol) in AcOH was added to the mixture,
and the reaction mixture was left to stir at room temperature for 72 h,
after which the reaction was completed. The reaction mixture was
quenched by the addition of water (100 mL), and the resulting
mixture was extracted with ethyl acetate (2 × 200 mL). The resulting
organic phases were combined and washed with water (100 mL), a
saturated solution of NaHCO3 in H2O (3 × 100 mL), and brine (50
mL) and then dried with Na2SO4. The mixture was filtered and
evaporated under reduced pressure to give the white solid 4b (5.9 g,
98%) which was used without further purification. 1H NMR (400
MHz, CDCl3): δ 6.94 (s, 1H, aromatic-H), 6.83 (s, 1H, aromatic-H),
6.09 (d, J = 8.0 Hz, 1H, NH), 4.67 (m, 1H, NH(CH)−), 3.72 (s, 3H,
OCOCH3), 2.84−2.97 (m, 3H), 2.30 (s, 3H, OCH3), 2.19−2.22 (m,
1H), 2.08 (dd, J = 12.4, 2.4 Hz, 1H), 1.48−1.81 (m, 16H), 1.29 (s,
3H), 1.23 (s, 3H), 1.17 (dd, J = 8.4, 6.9 Hz, 6H), 0.84−1.04 (m, 3H).
13C NMR (101 MHz, CDCl3): δ 178.1, 174.0, 170.0, 148.1, 146.2,
137.0, 132.9, 127.1, 117.8, 52.2, 50.2, 47.2, 45.4, 40.0, 38.0, 37.2, 37.2,
34.4, 33.6, 32.4, 29.4, 27.2, 26.4, 26.3, 26.1, 25.2, 23.1, 22.9, 21.0,
18.7, 16.4. FTIR (ATR): 3367, 2924, 1742, 1641, 1205, 912 cm−1.
UPLC−HRMS m/z: calcd for C32H48NO5, 526.3532 [M + H]+;
found, 526.3532.
Methyl 12-Hydroxyabieta-8,11,13-trien-18-oate (5a). Com-
pound 4a (4.53 g, 12.2 mmol) was dissolved in MeOH (216 mL).
K2CO3 (8.65 g, 62.6 mmol) was added, and the mixture was left to
agitate at room temperature for 35 min. The reaction mixture was
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filtered and concentrated under reduced pressure, diluted with water
(100 mL), and extracted with ethyl acetate (3 × 150 mL). The
combined organic phases were washed with water (200 mL), brine
(50 mL), and dried with anhydrous Na2SO4. The mixture was filtered
and evaporated under reduced pressure to yield the white solid 5a (3
g, 78%), which was used without further purification. 1H NMR (400
MHz, CDCl3): δ 6.82 (s, 1H, aromatic-H), 6.62 (s, 1H, aromatic-H),
4.60 (s, 1H), 3.66 (s, 3H, OCH3), 3.11 (sept, J = 6.8 Hz, 1H, 15-H),
2.78−2.83 (m, 2H), 2.16−2.23 (m, 2H), 1.33−1.84 (m, 7H), 1.26 (s,
3H), 1.23 (t, J = 6.6 Hz, 6H), 1.19 (s, 3H). 13C NMR (101 MHz,
CDCl3): δ 179.2, 150.8, 147.9, 131.7, 127.0, 126.7, 110.8, 52.0, 47.7,
44.8, 38.0, 36.9, 36.6, 29.3, 26.8, 25.0, 22.8, 22.5, 21.9, 18.6, 16.5.
FTIR (ATR): 3437, 2947, 1694, 1253, 859 cm−1. UPLC−HRMS m/
z: calcd for C21H31O3, 331.2273 [M + H]
+; found, 331.2273. All
analytical data are in agreement with literature values.59
Methyl-12-hydroxy-N-(abiet-8,11,13-trien-18-oyl) Cyclo-
hexyl-L-alanine (5b). Compound 4b (5.80 g, 11.0 mmol) was
dissolved in MeOH (275 mL) under magnetic stirring. K2CO3 (7.82
g, 56.5 mmol). The mixture was left to agitate for 35 min. The
reaction mixture was filtered and concentrated under reduced
pressure, diluted with water (100 mL), and extracted with ethyl
acetate (2 × 150 mL). The combined organic phases were washed
with water (200 mL) and brine (50 mL) and dried with Na2SO4. The
mixture was filtered and evaporated under reduced pressure to yield
the yellow solid 5b (5 g, 96%). The compound was used without
further purification. 1H NMR (400 MHz, CDCl3): δ 6.81 (s, 1H,
aromatic-H), 6.63 (s, 1H, aromatic-H), 6.10 (d, J = 8.0 Hz, 1H, NH),
4.65−4.71 (m, 1H, NH(CH)−), 3.72 (s, 3H, OCH3), 3.11 (sept, J =
6.9 Hz, 1H, 15-H), 2.76−2.89 (m, 2H), 2.21 (d, J = 12 Hz, 1H),
2.04−2.07 (m, 1H), 1.47−1.81 (m, 16H), 1.29 (s, 3H), 1.20−1.23
(m, 9H), 1.12−1.17 (m, 2H), 0.81−1.00 (m, 3H). 13C NMR (101
MHz, CDCl3): δ 178.3, 174.0, 150.9, 147.9, 131.8, 126.9, 126.7,
110.8, 52.2, 50.2, 47.4, 45.7, 40.1, 38.0, 37.2, 37.1, 34.4, 33.6, 32.4,
29.3, 26.8, 26.4, 26.3, 26.1, 25.2, 22.8, 22.6, 21.3, 18.8, 16.4. FTIR
(ATR): 3357, 2923, 1740, 1637, 1509, 1203, 885 cm−1. UPLC−
HRMS m/z: calcd for C30H46NO4, 484.3427 [M + H]
+; found,
484.3426.
Methyl 12-(3-Boc-aminopropoxy)abieta-8,11,13-trien-18-
oate (6a). Compound 5a (2.78 g, 8.42 mmol) was dissolved in
DMF (52 mL) under magnetic stirring. t-Butyl (3-bromopropyl)-
carbamate58 (2.36 g, 10.1 mmol) and Cs2CO3 (5.49 g, 16.8 mmol)
were added to the mixture that was left to agitate at room temperature
for 3.5 h, after which it was filtered, diluted with water (100 mL), and
extracted with ethyl acetate (3 × 100 mL). The resulting organic
phase was washed with water (200 mL), a saturated solution of
NaHCO3 in H2O (100 mL), and brine (50 mL) and then dried with
anhydrous Na2SO4. The residue was purified by flash chromatography
(SNAP 100 g, n-hexane/ethyl acetate, gradient 5 → 80%). After
evaporation of solvents, colorless oil 6a was obtained (3.8 g, 92%). 1H
NMR (400 MHz, CDCl3): δ 6.84 (s, 1H, aromatic-H), 6.69 (s, 1H,
aromatic-H), 4.90 (s, 1H, NH), 4.00 (t, J = 5.8 Hz, 2H), 3.66 (s, 3H,
OCH3), 3.35 (d, J = 6.0 Hz, 2H), 3.21 (sept, J = 6.9 Hz, 1H, 15-H),
2.79−2.83 (m, 2H), 2.21−2.26 (m, 2H), 1.95−2.01 (m, J = 5.99 Hz,
2H), 1.50−1.85 (m, 7H), 1.45 (s, 9H, OCO(CH3)3), 1.27 (s, 3H),
1.22 (s, 3H), 1.19 (t, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3):
δ 179.1, 156.0, 154.2, 147.5, 134.4, 126.9, 126.5, 107.1, 51.9, 47.7,
44.9, 38.1, 37.2, 36.6, 29.3, 28.5, 26.6, 25.0, 23.0, 22.7, 21.9, 18.6,
16.5. FTIR (ATR): 3370, 2932, 1695, 1453, 1244, 1166, 852 cm−1.
UPLC−HRMS m/z: calcd for C29H46NO5, 488.3376 [M + H]+;
found, 488.3376.
Methyl-12-(3-Boc-aminopropoxy)-N-(abiet-8,11,13-trien-
18-oyl) Cyclohexyl-L-alanine (6b). Compound 5b (3.00 g, 6.20
mmol) was dissolved in DMF (53 mL) under magnetic stirring. t-
Butyl (3-bromopropyl)carbamate58 (1.80 g, 7.44 mmol) and Cs2CO3
(4.10 g, 12.4 mmol) were added to the mixture which was left to
agitate at room temperature for 4.5 h. The reaction mixture was
diluted with water (100 mL) and extracted with ethyl acetate (3 ×
100 mL). The resulting organic phase was washed with water (200
mL), a saturated solution of NaHCO3 in H2O (100 mL), and brine
(50 mL) and then dried with anhydrous Na2SO4. The mixture was
filtered, evaporated under reduced pressure, and purified by flash
chromatography (SNAP 100 g, eluting n-hexane/ethyl acetate
gradient 10 → 80%). After evaporation of solvents, the white solid
powder 6b was obtained (2.4 g, 87%). 1H NMR (400 MHz, CDCl3):
δ 6.84 (s, 1H, aromatic-H), 6.69 (s, 1H, aromatic-H), 6.08 (d, J = 8.0
Hz, 1H, CONH), 4.91 (s, 1H, NHBoc), 4.64−4.70 (m, 1H,
NH(CH)−), 4.00 (t, J = 5.8 Hz, 2H), 3.72 (s, 3H, OCH3), 3.32−
3.37 (m, J = 6.1 Hz, 2H), 3.21 (sept, J = 6.9 Hz, 1H, 15-H), 2.77−
2.91 (m, 2H), 2.28 (d, J = 12.4 Hz, 1H), 2.08 (dd, J = 12.4, 2.0 Hz,
1H), 1.96−2.02 (m, 2H), 1.47−1.83 (m, 16H), 1.45 (s, 9H,
OCO(CH3)3), 1.30 (s, 3H), 1.25 (s, 3H), 1.19 (t, J = 7.2 Hz, 6H),
1.11−1.15 (m, 1H), 0.84−1.00 (m, 3H). 13C NMR (101 MHz,
CDCl3): δ 178.1, 174.0, 156.0, 154.2, 147.5, 134.5, 126.9, 126.6,
107.0, 52.2, 50.2, 47.4, 45.8, 40.1, 38.1, 37.5, 37.2, 34.4, 33.6, 32.4,
29.4, 28.5, 26.6, 26.4, 26.3, 26.1, 25.2, 23.0, 22.7, 21.3, 18.8, 16.4.
FTIR (ATR): 3304, 2923, 1752, 1165, 1062, 886 cm−1. UPLC−
HRMS m/z: calcd for C38H61N2O6, 641.4530 [M + H]
+; found,
641.4531.
Methyl 12-(3-Aminopropoxy)abieta-8,11,13-trien-18-oate
(7a). Compound 6a (3.80 g, 8.02 mmol) was dissolved in
dichloromethane (38 mL) under magnetic stirring. TFA (6.70 mL,
86.8 mmol) was added dropwise at 0 °C. The reaction mixture was
left to agitate at 0 °C for 2.7 h. After the reaction was completed, TFA
and dichloromethane were evaporated under reduced pressure. The
residue was diluted with ethyl acetate (200 mL) and a 1 M solution of
NaOH in H2O (100 mL). The aqueous phase was extracted with
ethyl acetate (200 mL). The combined organic phase was washed
with a 1 M solution of NaOH in H2O (50 mL) and brine (50 mL)
and then dried with anhydrous Na2SO4. The mixture was filtered and
evaporated under reduced pressure. After evaporation of solvents, the
white powder 7a was obtained (2.7 g, 87%) and used without further
purification. 1H NMR (400 MHz, CDCl3): δ 8.13 (s, 2H, NH2), 6.83
(s, 1H, aromatic-H), 6.68 (s, 1H, aromatic-H), 4.03 (t, J = 5.8 Hz,
2H), 3.65 (s, 3H, OCH3), 3.10−3.21 (m, 3H), 2.78−2.81 (m, 2H),
2.14−2.25 (m, 4H), 1.36−1.84 (m, 7H), 1.26 (s, 3H), 1.19 (s, 3H),
1.16 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3): δ 179.1,
154.3, 147.4, 134.5, 126.8, 126.5, 107.2, 66.0, 60.4, 51.9, 47.7, 47.7,
44.9, 39.3, 38.1, 37.2, 36.6, 32.4, 29.3, 26.6, 25.0, 22.9, 22.7, 21.9,
21.1, 18.6, 16.5, 14.2. FTIR (ATR): 2936, 1675, 1173, 1128, 834
cm−1. UPLC−HRMS m/z: calcd for C24H38NO3, 388.2852 [M +
H]+; found, 388.2850.
Methyl 12-(3-Aminopropoxy)-N-(abiet-8,11,13-trien-18-oyl)
Cyclohexyl-L-alanine (7b). Compound 6b (0.60 g, 0.94 mmol) was
dissolved in dichloromethane (6 mL) under magnetic stirring. TFA
(1.0 mL, 13 mmol) was added dropwise at 0 °C. The reaction mixture
was left to agitate at 0 °C for 2 h. After the reaction was completed,
TFA and dichloromethane were evaporated under reduced pressure.
The residue was diluted with ethyl acetate (70 mL) and a 1 M
solution of NaOH in H2O (30 mL). The aqueous phase was extracted
with ethyl acetate (2 × 50 mL). The combined organic phase was
washed with a 1 M solution of NaOH in H2O (50 mL) and brine (50
mL) and then dried with anhydrous Na2SO4. The mixture was filtered
and concentrated under reduced pressure. After evaporation of
solvents, the light pink solid 7b was obtained (0.479 g, 94%) and used
without further purification. 1H NMR (400 MHz, CDCl3): δ 6.83 (s,
1H, aromatic-H), 6.69 (s, 1H, aromatic-H), 6.10 (d, J = 8.4 Hz, 1H,
NH), 5.62 (s, 2H, NH2), 4.64−4.69 (m, 1H, NH(CH)−), 4.03 (t, J =
5.8 Hz, 2H), 3.72 (s, 3H, OCH3), 3.07−3.20 (m, 3H), 2.77−2.90 (m,
2H), 2.27 (d, J = 12.8 Hz, 1H), 2.04−2.11 (m, 3H), 1.44−1.80 (m,
16H), 1.29 (s, 3H), 1.23 (s, 3H), 1.17 (t, J = 7.0 Hz, 6H), 0.84−1.00
(m, 3H). 13C NMR (101 MHz, CDCl3): δ 178.2, 174.0, 154.0, 147.5,
134.6, 127.2, 126.7, 107.4, 66.0, 52.2, 50.2, 47.3, 45.8, 40.1, 38.8, 38.1,
37.4, 37.2, 34.4, 33.6, 32.4, 29.3, 26.6, 26.4, 26.3, 26.1, 25.2, 22.9,
22.7, 21.2, 18.7, 16.4 FTIR (ATR): 3362, 2923, 1741, 1500, 886
cm−1. UPLC−HRMS m/z: calcd for C33H53N2O4, 541.4005 [M +
H]+; found, 541.4004.
Preparation of CNF Films. Never-dried birch kraft pulp was used
to prepare CNF films, as reported previously.58 The pulp dispersion
was obtained by disintegrating using a high-pressure fluidizer
(Microfluidics, M-110Y, Microfluidics Int. Co., Newton, MA) and
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circulated for 6 passes. Prior to disintegration, the pulp had not been
chemically or enzymatically pretreated but washed into sodium form
in order to control the counter-ion type. Briefly, to prepare free-
standing films, 100 mL of CNF dispersion diluted to 0.85% was
filtered through a Sefar Nitex polyamine filament fabric for 30 min at
2.5 bar. The pore size of the fabric was 10 μm. The formed film was
then hot-pressed for 2 h at 100 °C and at 1800 kg/cm2 pressure, using
a Carver Laboratory Press (Fred S. Carver Inc.). More detailed
information about free-standing CNF films and their production can
be found elsewhere.33 The CNF films were stored at standard
conditions (23 °C, 50% RH) and cut according to the amounts
needed for each procedure.
Functionalization of CNF Films. The reaction was carried out
on a round-bottomed reaction flask, with magnetic stirring, using 5
cm diameter CNF films immersed in an aqueous solution (75 mL) of
CaCl2/NaHCO3 (0.05 M/0.01 M) and Na−CMC (270 mg), at 80
°C, for 4 h, after which the reaction mixture was poured out from the
flask and the CNF circle was washed, under magnetic stirring, with
deionized water (150 mL, 10 min), a 0.1 M solution of CH3COOH in
H2O (75 mL, 10 min), deionized water (150 mL, 10 min), a 0.4%
solution of NaHCO3 in H2O (75 mL, 1 h), and deionized water (150
mL, 10 min), dried overnight at 103 °C, and pressed between 2
carton sheets. After the carboxymethylation, one 5 cm diameter CNF
film was added to a round-bottomed flask containing EDC·HCl (0.02
M), HOBt (0.02 M), and Etax A (60 mL) and left under magnetic
stirring at room temperature for 1 h. Compounds 7a or 7b (0.02 M)
and DIPEA (0.04 M) were added, and the mixture was left to agitate
at room temperature for additional 24 h, after which it was poured out
of the reaction flask, and the CNF film was rinsed with Etax A (20
mL) and then washed 4 times, under magnetic stirring, with deionized
water (150 mL × 4, 10 min each washing), recovered, placed between
2 carton sheets, and left in an oven to dry overnight at 103 °C.
Mass Analysis. CNF-CMC-7b was directly compared to CNF-
CMC, unmodified CNF and compound 7b powder. Samples of CNF-
CMC-7b were analyzed from different production batches to confirm
reproducibility. CNF films were cut to an approximate size of 1 cm2
and inserted directly into the sample holder. To analyze 7b, a small
piece of double-sided carbon tape (∼1 cm2) was attached to an
aluminum block and a small amount of the compound was added to
the exposed adhesive surface. After light pressing with a spatula,
excess powder was removed by careful tipping and a gentle stream of
nitrogen. Surface analyses were carried out on a ToF-SIMS 5 mass
spectrometer (IONTOF GmbH, Germany) using a 30 keV Bi3
+
analysis beam. An electron flood gun was used for charge
compensation. CNF films were analyzed using spectrometry mode
data acquired from a surface area of 500 × 500 μm2 at 512 × 512
pixels in positive and negative ionization modes. Spectra were
acquired at a cycle time of 150 μs. An ion dose of 5 × 1011 ions/cm2
was maintained in order to stay below the static SIMS limit. The
powder sample was analyzed over a smaller target area of 250 × 250
μm2 at 256 × 256 pixels and with a lower dose of 1 × 1011 ions/cm2.
Data analysis was carried out on SurfaceLab software version 7
(IONTOF GmbH, Germany).
Water Contact Angle. The water contact angle was measured
using a CAM 2000 (KSV Instruments Ltd., Finland). CNF films (1 ×
1 cm2) were taped onto silica wafers, and a 6.5 μL droplet of Milli-Q
water was used for measuring. Built-in software analyzed the shape of
the droplet and obtained the water contact angle value using the
Young−Laplace equation. The static water contact angle was
measured for 60 s, but because of water droplets causing bending
of the CNF films, the water contact angles at 5 and 30 s are reported.
At least four measurements were taken for each sample, and mean
values are reported.
Streaming Current Measurements. The streaming current was
measured, at varying pressures (0−200 mbar), across streaming
channels formed by identically treated sample surfaces using the
microslit electrokinetic setup. Circular samples with a diameter of 15
mm were punched out from unmodified or modified CNF films and
fixed at movable stamps of a flow cell with a variable channel width.
The distance between the sample surfaces was set to 60 μm. The
measurements were performed as a function of the solution pH
starting in the alkaline pH range. For each pH condition tested, the
samples were equilibrated for about 40 min prior to measurement.
The electrolyte solutions used for the streaming current measure-
ments were prepared from vacuum-degassed deionized water (Milli-Q
Integral 3, Merck Millipore, Germany) by addition and/or
appropriate dilution of 0.1 M stock solutions.
X-ray Photoelectron Spectroscopy. Surface chemical analysis
of CNF films (1 × 1 cm2) was performed with a Kratos Analytical
AXIS Ultra electron spectrometer with monochromatic A1 Kα
irradiation at 100 W. Prior to measuring, the films were extracted in
acetone to remove impurities. CasaXPS software was used for data
analysis, and for the carbon regions, a specific four-component fitting
routine tailored for a cellulosic specimen was used.60 Low resolution
survey scans were used to determine the elemental surface
composition, and high resolution carbon C 1s and oxygen O 1s
regions were applied for a more detailed chemical evaluation.
Nitrogen contents were evaluated using long regional N 1s scan
that were recorded with survey resolution so that they could be
incorporated into survey quantifications. Three locations of each
sample were measured, and pure cellulose filter paper (Whatman) was
used as an in situ reference. The nominal analysis area was 300 × 700
μm2. Surface coverage was calculated by dividing the measured N or
C−C content with theoretical N or C−C content, respectively. The
theoretical N and C−C contents are based on the respective amounts
of nitrogen and carbon atoms with bonds to only other carbon or
hydrogen atoms in the chemical structure of the compounds.
Microbiology. S. aureus ATCC12598, S. aureus ATCC25923, S.
aureus MRSA 14TK3013, and E. coli DH5α were grown on Luria-
Bertani (LB, 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) agar
or in broth with shaking at 37 °C. L. lactis LAC460 and LAC471 were
grown in M17 media supplemented with 0.5% glucose. Overnight S.
aureus and E. coli cultures were serially diluted in one-fourth Ringer
solution (CaCl2 0.12 g/L, KCl 0.105 g/L, NaHCO3 0.05 g/L, NaCl
2.25 g/L), and overnight lactococcal cultures were diluted in minimal
media SD3 without sugar to certain concentrations for corresponding
assays. UAMS-1 and Mu50 were subcultured on Mueller−Hinton
agar (Lab M Limited, Lancashire, UK), at 37 °C, under aerobic
conditions. Liquid cultures were grown in Mueller−Hinton broth
(Lab M Limited), at 37 °C, under aerobic conditions.
Antimicrobial Activity of the Films. CNF films (5 cm
diameter) were cut into pieces (1 × 1 cm2) and incubated in 1.35
mL of bacterial suspensions with ∼105 CFU/mL, for 24 h, at 37 °C
and with shaking at 160 rpm for E. coli and S. aureus and at 30 °C with
shaking at 120 rpm, for L. lactis. Afterward, numeration of viable
bacteria was done.
Atomic Force Microscopy. Modified and unmodified free-
standing CNF films were imaged with a Nanoscope V MultiMode
scanning probe microscope (Corporation, Billerica, Massachusetts,
USA). The images were recorded with a tapping mode in air using
silicon cantilevers (NSC15/AIBS, MicroMasch, Tallinn, Estonia).
According to the manufacturer, the radius of the tip was <10 nm. At
least three places for each sample were imaged.
Antimicrobial Activity of Compounds 7a and 7b. S. aureus
ATCC12598 and E. coli DH5α were cultured with various
concentrations of compounds 7a or 7b. Honeycomb microtiter
plate wells were filled with 300 μL of LB media with 0.1% of overnight
culture. The final concentrations used for S. aureus and E. coli were 10,
20, 30, 40, 50, and 60 μM. Plates were incubated in Bioscreen C
(Labsystems, Helsinki, Finland), at 37 °C, with constant shaking.
Optical density was measured every hour with a wideband filter
(420−580 nm). All MIC determinations were done in triplicate, and
MIC was defined as the lowest concentration of compound for which
the OD values of all three parallels were below 0.2, in 12 h.
Measurement of ATP Efflux from S. aureus ATCC12598
Following Treatment with Compounds 7a and 7b. The efflux of
ATP from S. aureus ATCC12598 was measured using luciferin−
luciferase bioluminescence assay. Overnight culture of S. aureus was
collected and resuspended in one-fourth Ringer solution to ∼109
CFU/mL. One milliliter of cell suspension was incubated with
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compounds 7a or 7b at a final concentration of 100 μM, for 1 h at 37
°C, with shaking. After the incubation, 10 μL of cell free supernatants
was added to 100 μL of reaction solution in bioluminescence assay,
according to supplier’s protocol (Thermo Fisher, Waltham, MA,
USA). Bioluminescence was measured in a EnSprie multimode plate
reader (PerkinElmer, Waltham, MA, USA).
Scanning Electron Microscopy. Overnight culture of S. aureus
was diluted in one-fourth Ringer solution to ∼108 CFU/mL and
incubated with CNF films (1 × 1 cm2), for 24 h, or with compound
7b for 1 h, at 37 °C, with shaking. The cells were then collected by
centrifugation (5000g, 5 min), at 22 °C, resuspended in 0.1 M
phosphate buffer (pH 7.4), and fixed in 2% glutaraldehyde, for 2 h.
Cell samples subject to scanning electron microscopy (SEM) were
prepared according to standard protocol for the air drying
technique.61 After dehydration into absolute ethanol, specimens
were dried using Fluka hexamethyldisilazane, mounted into
aluminium stubs, coated with platinum, and examined under an FEI
Quanta 250 field emission gun scanning electron microscope at an
accelerating voltage of 5 kV (Electron Microscopy Unit, University of
Helsinki, Finland).
Biofilms. The S. aureus UAMS-1 strain was used for all biofilm
experiments. CNF and CNF-CMC-7b were cut into circles with a 0.5
cm diameter and placed in a flat-bottomed 48-well microtiter plate
(Greiner Bio-One, Kremsmünster, Austria). The samples were
submerged in 400 μL of Mueller−Hinton broth and inoculated
with 104 CFU S. aureus UAMS-1 (obtained from an overnight
culture). After 4 h incubation at 37 °C, medium was removed, the
samples were washed with 400 μL of PS (0.9% w/v NaCl), and a new
medium was added. After another 20 h, the medium was removed;
the samples were moved to a new well, and washed with 400 μL PS.
After washing, the biofilm was collected by 3 cycles of vortexing and
sonication for 30 s. The number of CFU was determined through
plating.
Artificial Dermis Experiments. The artificial dermis is composed
of two layers and was prepared, as previously described.62 The
artificial dermis was placed into a flat-bottomed 24-well microtiter
plate (Greiner Bio-One, Kremsmünster, Austria). The medium was
composed of Bolton Broth (Oxoid, Basingstoke, UK) containing 50%
plasma (Sigma-Aldrich), 5% freeze−thaw laked horse blood, and 0.5
U/mL heparin (Calbiochem, San Diego, USA). Medium (500 μL)
was pipetted on top of the artificial dermis, and subsequently, 10 μL
of an overnight culture of S. aureus UAMS-1 (containing approx 104
CFU) was added. The medium was added to the wells to a final
volume of 1 mL by pipetting around the artificial dermis to avoid
dehydration. CNF and CNF-CMC-7b were cut to fully cover the
expanded artificial dermis, placed on top of the artificial dermis, and
pushed onto the artificial dermis until they stuck to the surface. The
plate was cultivated at 37 °C for 24 h after which the material was
taken off and washed with 1 mL of PS. The artificial dermis was
collected in a tube containing 10 mL of PS. Biofilms were collected by
alternating vortexing and sonication for 30 s 3 times. The CFU counts
were determined by plating. Verification of the normal distribution of
the data was done using the Shapiro−Wilk test. The log 10 values for
the CFU counts between groups were compared by an independent
sample t-test for the material data. The artificial dermis data was
analyzed using a one-way analysis of variance (ANOVA) Bonferroni
analysis. The statistical analyses were carried out with SPSS version 25
(SPSS Inc., Chicago, USA).
Determination of MIC on UAMS-1 and Mu50 Strains. The
MIC was determined according to the EUCAST broth microdilution
guidelines.63 The MIC was determined in triplicate using a flat-
bottomed 96 well microtiter plate (Greiner Bio-One, Kremsmünster,
Austria) using Mueller−Hinton broth as growth medium. The tested
concentrations ranged from 0.25 to 128 μg/mL. The overnight
planktonic cultures were adjusted to obtain a final inoculum of 5 ×
105 CFU/mL in the wells. Plates were incubated at 37 °C for 24 h,
and optical density at 590 nm was determined using an Envision plate
reader (PerkinElmer, Waltham, MA, USA). The MIC values were
determined as the lowest concentration of 7b at which growth was
completely inhibited.
Blood Hemolysis. Whole blood (1.0 mL) collected from healthy
human donors (Scottish National and Transfusion Services, Scotland,
Sample Governance Submission 19∼17) was pipetted into an
Eppendorf tube and centrifuged at 500g, for 5 min in an Heraeus
Megafuge 16 (Thermo Scientific), and the levels of hematocrit (red,
lower layer) and plasma (yellowish, upper layer) were marked with
pen on the Eppendorf tube. The upper fraction (plasma) was gently
removed via a micropipettor and replaced with a cold 150 mM
solution of NaCl in Milli-Q to the marked line. The Eppendorf tube
was closed and inverted six times to gently disperse the lower fraction
(hematocrit) in the NaCl solution. The mixture was subsequently
centrifuged at 500g, for 5 min, and again the supernatant solution was
removed and replaced with a cold 150 mM solution of NaCl in water
to further wash the erythrocytes. The supernatant was again aspirated
and replaced with 1× phosphate-buffered saline (PBS) at pH 7.4,
followed with six tube inversions to uniformly mix the erythrocytes
with the PBS. The erythrocytes were then diluted in a 1:50 ratio in 50
mL falcons (Corning Inc. Life Sciences) with sterile PBS after which
12 mm diameter circles of plain CNF and CNF-CMC-7b films were
individually placed at the bottom of a 24-well plate (Corning Inc. Life
Sciences) and washed with sterile PBS. The erythrocyte dilution (2
mL) was placed into each corresponding well, 2 mL of the dilution
was placed in empty wells, and 200 μL of 20% Triton X-100 and 1800
μL of PBS were placed in the last wells as control. All wells were
visually inspected which should be turbid and settle if left
undisturbed. The plates were incubated for 1 h, at 37 °C, in a 5%
CO2 atmosphere in a MCO-170M multi gas incubator (Panasonic
Biomedical), and 1 mL of samples from the wells were subsequently
collected in sterile 1.5 mL Eppendorf tubes and centrifuged at 500g
for 5 min to pellet the intact erythrocytes. Supernatant from the
Eppendorf tubes (200 μL) was transferred to a 96-well plate
(PerkinElmer Inc.) and the absorbance was measured at 415 nm,
using a Flex Station 3 multi-mode microplate reader (Molecular
Devices). The negative background absorbance was subtracted from
all samples and each value normalized to the positive Triton-treated
control (100% lysis) to calculate percent hemolysis.
Cell Viability. Human skin fibroblasts were cultured in a 75 cm2
flask (Corning Inc. Life Sciences) in Dulbecco’s modified Eagle’s
medium (HyClone) supplemented with 10% fetal bovine serum, 1%
sodium pyruvate, 1% nonessential amino acids, 1% L-glutamine,
penicillin (100 IU/mL), and streptomycin (100 mg/mL) (all from
HyClone). The cultures were maintained in a Heracell 150i incubator
(Thermo Fisher Scientific) in an atmosphere of 5% CO2 and 95%
relative humidity. The growth medium was changed every other day
until the time of use. CNF and CNF-CMC-7b films were cut into 12
mm diameter circles, individually placed at the bottom of a 24-well
plate (Corning Inc. Life Sciences), and washed with sterile PBS.
Subsequently, the fibroblasts were detached using a trypsin−PBS−
EDTA solution, and 4 × 104 human fibroblasts were placed on top of
the materials in the 24-well plate. The cells were allowed to attach and
incubate with the films, for 72 h, with the medium replaced every
other day. After the incubation period, the medium was aspirated and
the cells and materials were washed twice with fresh sterile PBS.
Then, 1 mL of CellTiter-Glo reagent assay (Promega Corporation)
was added to each well according to the manufacturer’s instructions.
Luminescence was measured using a Varioskan Lux (Thermo Fisher
Scientific). The luminescence of the sample wells was compared with
positive (PBS) and negative (2% Triton X-100) controls. All assays
were carried out at least in quadruplicate.
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Iṡçan, G.; Krogerus, S.; Yli-Kauhaluoma, J.; Moreira, V. M.; Tammela,
P. Antibacterial profiling of abietane-type diterpenoids. Bioorg. Med.
Chem. 2017, 25, 132−137.
(44) Vahermo, M.; Krogerus, S.; Nasereddin, A.; Kaiser, M.; Brun,
R.; Jaffe, C. L.; Yli-Kauhaluoma, J.; Moreira, V. M. Antiprotozoal
activity of dehydroabietic acid derivatives against Leishmania donovani
and Trypanosoma cruzi. MedChemComm 2016, 7, 457−463.
(45) Manner, S.; Vahermo, M.; Skogman, M. E.; Krogerus, S.;
Vuorela, P. M.; Yli-Kauhaluoma, J.; Fallarero, A.; Moreira, V. M. New
derivatives of dehydroabietic acid target planktonic and biofilm
bacteria in Staphylococcus aureus and effectively disrupt bacterial
membrane integrity. Eur. J. Med. Chem. 2015, 102, 68−79.
(46) Belu, A. M.; Graham, D. J.; Castner, D. G. Time-of-Flight
Secondary Ion Mass Spectrometry: Techniques and Applications for
the Characterization of Biomaterial Surfaces. Biomaterials 2003, 24,
3635−3653.
(47) Kempson, I. M.; Prestidge, C. A. Mass Spectrometry Imaging of
Pharmaceuticals: From Tablets to Tissues. In Analytical Techniques in
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